Nitto Denko Avecia announced the opening of its new oligonucleotide API (active pharmaceutical ingredients) manufacturing facility in Milford, MA. The opening will commence with a ribbon cutting ceremony in August 2017 onsite at the Milford, MA facility. The ceremony will open with remarks from;
- Hideo Takasaki, CEO, Nitto Denko Corporation
- Jay Ash, MA Secretary for the Executive Office of Housing and Economic Development, followed by keynotes from;
- Mark Alles, CEO, Celgene Corporation
- Barry Greene, President, Alnylam Pharmaceuticals
The expansion will add 20,000 square feet of manufacturing and office space at Avecia's Milford, MA site and provide CGMP oligonucleotide manufacturing capacity up to 1.8mol. The total capacity of Avecia's Milford, MA site has now more than doubled up to 3.0mol, which makes Avecia in Milford, MA the largest oligonucleotide manufacturing site in the world.
"This expansion will help Avecia's clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials as planned. "Avecia takes pride that our engineers have introduced novel technology, executed this expansion in record time, and in close collaboration with A/Z Corporation to ensure the timely supply of novel oligonucleotide therapeutics," said Avecia's president Detlef Rethage.
Avecia has added more than 120 jobs in the last 12 months in Milford, MA and currently has more than 50 open positions at its four locations in MA, OH, and CA. The new positions will specialize in microbiology, analytical chemistry, manufacturing, quality assurance and engineering.